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http://dx.doi.org/10.1016/j.stemcr.2017.01.005SUMMARYClinical translation of cell-based strategies for regenerativemedicine demands predictable in vivo performance where the use of sera dur-
ing in vitro preparation inherently limits the efficacy and reproducibility. Here, we present a bioinspired approach by serum-free pre-con-
ditioning of human periosteum-derived cells, followed by their assembly into microaggregates simultaneously primed with bone
morphogenetic protein 2 (BMP-2). Pre-conditioning resulted in a more potent progenitor cell population, while aggregation induced os-
teochondrogenic differentiation, further enhanced by BMP-2 stimulation. Ectopic implantation displayed a cascade of events that closely
resembled the natural endochondral process resulting in bone ossicle formation. Assessment in a critical size long-bone defect in immu-
nodeficientmice demonstrated successful bridging of the defect within 4 weeks, with active contribution of the implanted cells. In short,
the presented serum-free process represents a biomimetic strategy, resulting in a cartilage tissue intermediate that, upon implantation,
robustly leads to the healing of a large long-bone defect.INTRODUCTION
Cell-based advanced therapy medicinal products (ATMPs)
have the potential to transform our health care systems,
especially for patients with failing intrinsic tissue regenera-
tion such as complex and large bone defects in compro-
mised biological conditions (Einhorn and Gerstenfeld,
2015). The standard approach of this strategy typically
includes: (1) donor cells to form tissues together with avail-
able host cells, (2) stimulatory factors to direct cellular pro-
cesses, and (3) biomaterials to provide cells with 3D cues
(Leijten and Khademhosseini, 2016). Despite major ad-
vances in the design, production and in vitro performance
of ATMPs, only a fraction displays suitable characteristics
for clinical translation (Leijten et al., 2014). Major reasons
for this lack in clinical monetization of research efforts
can be attributed to a poor design and lack of robust
manufacturing protocols. In terms of the design, a biomi-
metic strategy inspired by developmental embryology pro-
vides a scientific foundation and offers key clues regarding
the main players, sequences of events and 3D stimulatory
cues in postnatal fracture healing (Lenas et al., 2009; Ingber
et al., 2006; Ueno et al., 2001; Knothe Tate et al., 2008).
Previous reports established that large bone defects mainly
heal through the formation of an intermediate cartilagi-
nous callus (Einhorn and Gerstenfeld, 2015). Conse-
quently, in order to mimic the native healing process of a
large long-bone defect, a cell-based ATMP was designed to758 Stem Cell Reports j Vol. 8 j 758–772 j March 14, 2017 j ª 2017 The Aut
This is an open access article under the CC BY-NC-ND license (http://creativdevelop along the endochondral route. However, the
classical cell source for bone repair used today is a bone
marrow aspirate from the iliac crest. Yet, bone marrow-
derived cells exclusively contribute to fracture healing by
direct bone formation (Colnot, 2009). In consequence,
periosteum-derived cells (PDCs), the main contributing
cells in endochondral fracture healing, may be a more
clinically relevant cell source (Colnot, 2009; Colnot et al.,
2012). Moreover, PDCs have shown osteochondrogenic
potential both in vitro and in vivo (De Bari et al., 2006).
As stimulatory factors, bone morphogenetic proteins
(BMPs) are of relevance due to their crucial role in PDC-
mediated fracture healing (Tsuji et al., 2006; Chappuis
et al., 2012). Moreover, specific BMP ligands have been
shown to induce human PDC (hPDC)-mediated ectopic
ossicle formation (Bolander et al., 2016).
Approval for clinical applications of BMP-2 and BMP-7
has already been obtained. However, their use has been
associated with unpredictable bone formation due to a
number of reasons, including the delivery of the supraphy-
siological levels required for progenitor cell recruitment
(Shields et al., 2006; Pobloth et al., 2015). In vitro primed
cell-based ATMPs could overcome this hurdle by delivery
of the crucial number of progenitors required, appropri-
ately primed in vitro to regenerate the damaged tissue
in vivo. However, until now, in vitro stimulation of progen-
itor cells for in vivo tissue regeneration has been chal-
lenging. Long-term in vitro stimulated cells often fail tohor(s).
ecommons.org/licenses/by-nc-nd/4.0/).
integrate with the host, likely due to thematurity of the tis-
sue (Yamashita et al., 2015). Shorter priming periods on the
other hand, seem not to be sufficient in terms of clinically
relevant results (Eyckmans et al., 2013). A potential reason
for this can be that the in vitro priming is carried out inme-
dium containing serum (Ryan, 1979). Indeed, serum con-
tains an undefined and variable range of factors such as
cytokines and inhibitors that bind to cell surface receptors.
In consequence, batch-to-batch variability significantly af-
fects the characteristics of cell-based implants, leading to
unpredictable behavior and outcomes (Jung et al., 2012;
Baker, 2016).
It was therefore hypothesized that serum-free pre-condi-
tioning of hPDCs prior to growth factor treatment could
improve the cellular response. A chemically defined
serum-free pre-conditioning regime of hPDCs was devel-
oped that led to an adapted progenitor cell population
with improved differentiation capacity. When assembling
the pre-conditioned cells into microaggregates, mimicking
cellular condensations by providing biomimetic 3D cues,
and simultaneously treating them with BMP-2, cell specifi-
cation toward the osteochondrogenic lineages was
observed. Interestingly, physiologically relevant levels of
autocrine and paracrine growth factors were secreted by
the fate-steered, engineered microtissues. In vivo, the self-
sustained implant proceeded to mature into endochondral
bone, recapitulating long-bone fracture healing. We antic-
ipate that the proposed serum-free strategy can be trans-
lated in a wide array of applications within the field of
regenerative medicine.RESULTS
Pre-conditioning Induces a Cellular Identity Shift
toward a CD34+ Progenitor
To define the culture conditions that maintained cell
viability without enhancing proliferation, hPDCs were
cultured for 6 days in a chemically defined medium
(CDM) and compared with hPDCs cultured in growth me-
dium (GM) containing 10% fetal bovine serum. After 24 hr,
as well as after 6 days of culture, cells in CDM showed no
cell proliferation compared with GM-cultured cells (Fig-
ure 1A). However, after 6 days, elevated DNA contents
per cell were seen in pre-conditioned cells (Figure 1B). To
investigate whether adaptations in the cell cycle were
caused, expression levels of cell cycle markers cyclin-
dependent kinase 1 (CDK1), cyclin E1 (CCNE1), and bacu-
loviral inhibitor of apoptosis repeat-containing 5 (BIRC5)
were determined. Expression of CDK1, essential for cell cy-
cle progression during S and G2 phases, displayed a 6-fold
upregulation in pre-conditioned cells (Figure 1C). Simi-
larly, a 7-fold increased transcript level of CCNE1, requiredfor G1/S transition was found (Figure 1D). Interestingly, a
10-fold increased level of BIRC5, a negative regulator of
apoptosis during the G2/M phase was also seen in pre-
conditioned cells (Figure 1E). To further investigate
changes in cellular identity, flow cytometry was performed
to characterize the expression of conventional mesen-
chymal stem cell markers (Figure 1F). It was shown that
over 97% of cells grown in GM were positive for CD73,
CD90, and CD105, whereas only 81% of cells cultured in
CDM were positive for CD105. Cells from both conditions
were negative for CD14, CD20, and CD45 (Figure S1A), but
70% of the CDM pre-conditioned cells displayed positivity
for CD34 (Figure 1F), a phenomenon that was not seen in
human bone marrow stromal cells (Figure S1B). Kinetic
studies by mRNA transcript analysis and flow cytometry
revealed a gradual increase in CD34 expression as well
as in the amount of receptors per cell during pre-condition-
ing (Figures 1G and 1H). The opposite trend was seen
for CD105, where pre-conditioning led to a decreased
expression ofCD105 cells as well as a reduced amount of re-
ceptors per cell (Figures 1I and 1J). Of note, mRNA tran-
script levels of CD34 displayed a 70- and 20-fold higher
expression in hPDCs from individual donors at passage
zero (p0) compared with GM-expanded cells at passage
6 (p6), respectively (Figure S1C). In addition, CDMpre-con-
ditioning led to increased cell size and less granularity
(Figure S1D). However, no significant aberrations were
observed in karyotype analysis (Figure S1E).
To investigate whether the pre-conditioning regimen
may lead to an enhanced BMP response, mRNA transcript
analysis of BMP type 1 and type 2 receptors was performed.
CDM pre-conditioned cells displayed an increased expres-
sion of BMP type 1 (ALK1, ALK2, ALK3, and ALK6) and
type 2 (BMPR2, ACVR2a, and ACVR2b) receptors, in com-
parison with standard cultured cells (Figure 1K). To further
characterize the CDM-grown cells, mRNA transcript anal-
ysis displayed elevated expression of secreted factors rele-
vant to bone formation: a 10-, 12-, and 4.6-fold increase
for basic fibroblast growth factor (FGF-2), vascular endothe-
lial growth factor (VEGF), and matrix metallopeptidase
9 (MMP9) expression, respectively (Figure 1L). These results
were also confirmed on the protein level through an ELISA
assay on conditioned medium (Figure 1M). Combined,
these data indicate that the serum-free pre-conditioning
led to an adapted cellular phenotype specific for hPDCs.
Reduced positivity for MSC markers was correlated to
increased positivity for CD34 and elevated expression of
BMP receptors, identifying a switch in cellular identity.
Enhanced Effect of BMP-2-Induced Differentiation in
Pre-conditioned hPDCs
Next,we set out to investigatewhether these changeswould
translate into distinct responses upon BMP treatment.Stem Cell Reports j Vol. 8 j 758–772 j March 14, 2017 759
Figure 1. Serum-free Pre-conditioning for 6 Days Affected Cellular Identity
(A) DNA quantification in cells pre-conditioned in CDM or GM normalized to day 0.
(B–E) DNA per cell after 6 days of pre-conditioning (B). Pre-conditioning induced expression of cell cycle regulators CDK1 (C), CCNE1(D),
and BIRC5 (E).
(F) Flow cytometry analysis after pre-conditioning for MSC markers CD73, CD90, and CD105 together with CD34.
(G and H) Kinetics studies on (G) the mRNA transcript level of CD34 and (H) flow cytometry data on the number of CD34 molecules per cell.
(I and J) Kinetic studies on (I) the mRNA transcript level of CD105 and (J) flow cytometry data on the number of CD105 molecules per cell.
(K–M) mRNA transcript analysis of BMP type 1 and type 2 receptors (K), FGF2, VEGF, and MMP9 (L), confirmed on the protein level from
conditioned medium (M).
n = 3, *p < 0.05, **p < 0.01, ***p < 0.001.hPDCs were pre-conditioned in CDM or GM followed by
24 hr, or 3 or 6 days of BMP-2 stimulation in CDM. After
6 days, morphological differences between the two condi-
tions were seen (Figure 2A). Cells pre-conditioned under
serum-containing conditions displayed a heterogeneous
cell populationwith a fractionpossessingapolygonal shape
resembling differentiating cells (black arrows). Interest-
ingly, BMP-2-stimulated cells pre-conditioned in CDM dis-
played a more homogeneous cell morphology in which
the majority of the cells exhibited a polygonal shape (black
arrows). This phenomenonwas associated with an increase760 Stem Cell Reports j Vol. 8 j 758–772 j March 14, 2017in alkalinephosphatase (ALP) activity since a3- and1.5-fold
increasewasobserved after 3 and6daysofBMPstimulation,
respectively (Figure2B). To confirmthedifferentiation stage
of the cells, mRNA transcripts were analyzed. After 24 hr of
BMP-2 stimulation, a 2-fold upregulation of SRY (sex deter-
mining region Y)-Box 9 (SOX9) was seen in BMP-2 stimu-
lated samples and this effect was further elevated to over
10-fold in day 3 and day 6 samples (Figure 2C). Moreover,
CDM pre-conditioned cells displayed a 1.6- and 2-fold
elevated expression compared with serum conditions
in day 3 and 6 samples. Similarly, the osteogenic marker
Figure 2. Serum-free Pre-conditioning led to Enhanced BMP-2-Induced Osteochondrogenic Differentiation In Vitro
After 6 days of pre-conditioning followed by 6 days of BMP-2 stimulation in CDM, a difference in response to BMP-2 was observed.
(A) Bright-field images after 6 days of BMP-2 stimulation indicating differentiated cells (black arrows).
(B–E) BMP-2 stimulation induced elevated ALP activity(B). mRNA transcripts displayed elevated expression of SOX9 (C), OSX (D), and
ID1 (E) after 24 hr, and 3 and 6 days of BMP-2 stimulation.
(F) IHC for SOX9 (red) and OSX (green) with DAPI (blue) as nuclear stain after 6 days of BMP-2 stimulation.
(G–J) Quantification of merged confocal images expressed as relative units (RU) normalized to DAPI (G). mRNA transcript analysis after
pre-conditioning of hPDCs followed by 6 days of stimulation of BMP-2, -6, -7, -9, and GDF5 depicted by SOX9 (H), OSX (I), and ID1 (J). Scale
bar, 50 mm; n = 3, */#p < 0.05, **/##p < 0.01, ***/###p < 0.001 where # represents statistical significance to BMP-2 treated condition.
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Osterix (OSX) was upregulated in CDM pre-conditioned
cells with a 1.6- and 1.9-fold increase after 3 and 6 days,
respectively (Figure 2D). In support of the enhanced osteo-
chondrogenic differentiation profiles of CDM pre-condi-
tioned cells, analysis of collagen type 2a (COLL2A1),
collagen type 10 (COLL10A1), runt-related transcription
factor 2 (RUNX2), and collagen type 1 (COLL1A1) is
presented in Figure S2A. Activated BMP signaling was
confirmedby inhibitorofdifferentiation1 (ID1) expression,
a 2.5- and 2-fold higher expression was seen in CDM pre-
conditioned cells after 3 and6days, respectively (Figure 2E).
Pre-conditioned Cells Undergo Osteochondrogenic
Differentiation
The mRNA transcript analysis suggested a robust chondro-
genic as well as osteogenic differentiation in cells pre-
conditioned in CDM. To define whether there was a
subpopulation of cells that differentiated toward a specific
lineage, a combined immunohistochemistry (IHC) for
SOX9 (red), OSX (green), and DAPI (blue) was performed.
Cells displayed similar positivity for SOX9 in both
BMP-2-stimulated conditions, but a larger fraction of
OSX-positive cells in CDM pre-conditioned cells, mainly
in combination with SOX9 positivity (Figure 2F). Quantifi-
cation of merged images confirmed elevated positivity for
both markers in CDM pre-conditioned cells followed by
BMP-2 stimulation (Figure 2G). Of note, the enhanced
BMP response in CDM pre-conditioned cells was not spe-
cific for BMP-2. In fact, this was consistent for a range
of BMPs including BMP-4, -6, -7, -9, and GDF5. Upon
mRNA transcript analysis of SOX9 and OSX, a more
than 2-fold increase was seen for all BMPs in cells pre-
conditioned in CDM (Figures 2H and 2I). A similar phe-
nomenon was seen for the BMP target gene ID1 (Figure 2J).
The elevated osteochondrogenic differentiation was
further supported by analysis of aggrecan (ACAN), osteocal-
cin (OCN), distal-less homeobox 5 (DLX5), BMP-2, and
VEGF (Figure S2B). The effect of CDM pre-conditioning
was confirmed in young and adult donors, and presented
in Supplemental Information (Figure S3A–S3G). Upon
ectopic in vivo implantation for 3 weeks, CDM pre-condi-
tioning followed by BMP-2 stimulation led to elevated
cartilaginous matrix formation compared with GM-stimu-
lated cells (Figure S4). These data show that serum-free pre-
conditioning uniquely leads to an increased differentiation
response to several BMP ligands. This effect is independent
of donor gender or age and in vitro findings were translated
in the in vivo setting.
Enhanced Differentiation due to an Altered BMP
Pathway Activation
Western blot analysis of the pre-conditioned cells after
60 min of BMP-2 stimulation displayed an altered BMP762 Stem Cell Reports j Vol. 8 j 758–772 j March 14, 2017signaling pathway activation compared with GM control
(Figures 3A–3E). Quantification displayed elevated phos-
phorylation of the SMAD1/5/8 complex and p38 in the
CDM pre-conditioned cells, while cells stimulated under
GM conditions displayed phosphorylation of ERK1/2 and
p38 (Figures 3F–3H). Since BMP signaling is known to
crosstalk with downstream regulators of Wnt and trans-
forming growth factor b, the activation of b-catenin and
the SMAD2/3 complex was investigated. It was shown
that BMP stimulation under GM conditions led to an
increased level of active b-catenin, while CDM pre-condi-
tioned cells displayed phosphorylation of the SMAD2/3
complex (Figures 3I and 3J). Together, these data confirm
that the enhanced osteochondrogenic differentiation
observed in the CDM pre-conditioned cells was associated
with an altered downstream signaling activation.
The CD34+ Cell Population Displayed a More Potent
Osteochondrogenic Potential
To investigate whether it was the CD34+ cell population
that was more BMP responsive, pre-conditioned CD34+
cells were sorted and compared with the total CDM popu-
lation. On the mRNA transcript level, elevated CD34
expression was confirmed (Figure 3K). Interestingly, an up-
regulated expression of BMP receptors ALK1 and ALK6 was
confirmed, whereas an upregulated trend was detected for
ALK2 and BMPR2, and no difference was found for ALK3
(Figure 3L). Upon BMP-2 stimulation, the CD34+ popula-
tion displayed a 2- and 5-fold elevated expression of
SOX9 and OSX, respectively (Figure 3M). Cluster analysis
displayed a correlation between elevated CD34, ALK1,
ALK2, ALK6, BMRP2, SOX9, and OSX expression (Fig-
ure 3N), and specific grouping of the CD34+ population
was depicted in a constellation plot (Figure 3O). Com-
bined, these data indicate that the increased osteochondro-
genic response is related to the CD34+ cell population.
Bioinspired 3D Aggregation and BMP-2 Stimulation
Reduce Stemness and Cell Size
Cellular condensations precede limb bud development
and therefore aggregation was investigated in order to
enhance cell specification in hPDCs by providing biomi-
metic 3D cues. Aggregate size affects mechanical cues,
nutrient flux, and cell-cell interaction forces. Optimal
aggregate size was determined through an in vitro
screening of 50, 100, and 250 hPDCs/aggregate. Cell ag-
gregation was induced on pre-conditioned cells with or
without BMP-2 stimulation for 6 days, after which the
samples were analyzed by microscopy, mRNA transcript
analysis, histology, and IHC. 2D-cultured cells were
included as a control. Bright-field images showed that
uniform aggregates were formed in the 100 and 250
cell aggregate size (Figure S5A). Next, the influence of
Figure 3. Altered Pathway Activation upon Pre-conditioning with CD34+ Cells Displaying a More Potent Osteochondro-Progenitor
Cell Population
(A–J) Pathway activation following pre-conditioning and BMP-2 stimulation investigated by western blot and subsequent quantification
for (A) and (F) p-SMAD1/5/8, (B) and (G) p-Erk1/2, (C) and (H) p-p38, (D) and (I) active b-catenin, and (E) and (J) p-SMAD2/3.
(K and L) Following separation of the CD34+ cell population, elevated expression of CD34 (K) and BMP receptors (L) were seen.
(M) Following 6 days of BMP-2 stimulation the CD34+ hPDCs showed elevated differentiation depicted by SOX9 and OSX expression.
(N) Cluster analysis displayed a correlation between the expression of CD34, BMP receptors, and differentiation markers.
(O) A constellation plot showed clear grouping of CD34+ cells and the total cell population.
n = 3, *p < 0.05, **p < 0.01, ***p < 0.001.aggregation and BMP-2 stimulation on the MSC markers
CD73, CD90, and CD105 was investigated by flow cy-
tometry (Figure 4A). The analysis of CD73 showed a
reduced positivity from 96% to below 80% in aggregated
cells in the presence of BMP-2. This effect was even more
pronounced for CD90 with less than 45% positivity.
The largest reduction was seen when analyzing CD105
expression: only 19% of the cells cultured in an aggre-
gate system and stimulated with BMP-2 were positive
compared with 96% in only aggregated cells. Moreover,
aggregation induced a reduction in cell size compared
with both the control and BMP-2-stimulated cells in 2D
(Figure S5B). These data indicate that an aggregation-
dependent effect on the CD34-enriched hPDC popula-tion was induced, further enhanced in combination
with BMP-2 stimulation.
Aggregation and BMP-2 Treatment Synergistically
Enhance In Vitro Osteochondrogenic Differentiation
Upon mRNA transcript analysis, BMP-2 stimulation
induced an elevated expression of the chondrogenic
markers SOX9, COLL2A1, and ACAN (Figure 4B), and the
largest increase in expression was found in cells stimulated
in 2D. Upon analysis of osteogenic markers RUNX2, ALP,
andOSX, a synergistic effect of aggregation in combination
with BMP-2 stimulation was seen, which was further
increased with aggregate size (Figure 4C). The upregulated
differentiation profile could be correlated to the expressionStem Cell Reports j Vol. 8 j 758–772 j March 14, 2017 763
Figure 4. The Number of Cells per Aggregate Affected Osteogenic and Chondrogenic Cell Specification
To determine optimal size, aggregates of 50, 100, and 250 cells/aggregate were investigated after 6 days of aggregation.
(A–D) Aggregation and BMP-2 stimulation induced a shift in MSC marker expression and a reduction when both factors were combined (A).
mRNA transcript analysis of (B) chondrogenic, (C) osteogenic, and (D) BMP signaling and angiogenic markers indicated that both ag-
gregation, aggregation size and BMP-2 stimulation affected cell differentiation. n = 3, statistical significance to non-BMP-2-stimulated
conditions: *p < 0.05, **p < 0.01, ***p < 0.001 and to 2D BMP-2 conditions: #p < 0.05, ##p < 0.01, ###p < 0.001.of the transcriptional regulator DLX5, the BMP marker
gene ID1, and the angiogenic marker VEGF (Figure 4D).
Next, the gene expression data were confirmed on the
protein level by IHC for SOX9 (red), OSX (green), and
DAPI (blue) (Figure S6A). Histology for H&E, Alcian blue
(AB) and alizarin red displayed the initiation of matrix for-
mation in the in vitro stimulated microtissues, depicted in
stained sections of 250 hPDCs/aggregate (Figure S6B).
These data confirmed the induction of osteochondrogenic
cell specification induced by the 3D environment, in
which the aggregate size steered differentiation in combi-
nation with BMP-2.
In Vivo Ectopic Tissue Formation
Based on the in vitro analysis, the size of 250 cells/aggre-
gate was selected for in vivo evaluation combined with or
without simultaneous BMP-2 stimulation in parallel to
2D-stimulated cultures. In addition, 2D cultures stimulated
with BMP-2 for 6 days followed by 24 hr of aggregation in
the absence of BMP-2 were included in order to evaluate
the combined as well as the individual effects of aggrega-
tion and BMP stimulation. Upon analysis of implants har-764 Stem Cell Reports j Vol. 8 j 758–772 j March 14, 2017vested after 1 week, H&E staining displayed microvessel
formation (black arrows) which was shown to be 2-fold
higher in samples treated with BMP-2. This effect was
synergistic when combined with aggregation (Figures 5A
and 5E). An AB staining revealed the deposition of cartilag-
inousmatrix, rich inGAG content, in BMP-2-treated aggre-
gates (black arrows) (Figure 5B), confirmed by Masson’s
trichrome (MT) stain, which displayed a more mature ma-
trix tissue with a denser collagen content (black arrows)
(Figure 5C). IHC for p-SMAD1/5/8 showed active BMP
signaling in explants that were cultivated in the presence
of BMP-2 or aggregated, depicted by brownnuclei (black ar-
rows) (Figure 5D).When combined, the number of positive
nuclei was further increased (black arrows). These datawere
confirmed by quantification of positive nuclei normalized
to the total number of nuclei (Figure 5F). Due to the active
BMP signaling, analysis of endogenous BMP-2 produc-
tion was investigated by ELISA in conditioned medium
at the time of implantation (Figure 5G). The combined
effect of BMP-2 stimulation and aggregation displayed
1.5-fold higher BMP-2 protein levels in conditioned
medium compared with fresh stimulation medium. This
Figure 5. In Vitro Priming Leads to an In Vivo Cartilage Intermediate 1 Week Post Transplantation
Histology of tissue constructs 1 week after in vivo subcutaneous implantation displayed that both BMP-2 stimulation and aggregation
affected in vivo tissue formation.
(A) H&E staining showed microvessel formation (black arrows).
(B and C) Denser AB staining revealed more cartilage matrix accumulation (black arrows) (B), confirmed by denser collagen staining by MT
staining (black arrows) (C).
(D) Upon IHC for p-SMAD1/5/8 as a marker for active BMP signaling, positive nuclei (brown stain, black arrows) were seen in samples
stimulated by BMP-2 and/or aggregation.
(E and F) Quantification showed that the combined stimulation of BMP-2 and aggregation elevated the number of microvessels (E) and
positive nuclei for p-SMAD1/5/8 (F).
(G) BMP-2 production by stimulated cells were confirmed in conditioned medium by ELISA.
(H) Enhanced transcripts for BMP-2 on implants at the time of implantation.
Scale bars, 20 mm. n = 4, *p < 0.05, **p < 0.01, ***p < 0.001.
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finding was further confirmed by enhanced mRNA tran-
script levels of BMP-2 expression at the time of implanta-
tion (Figure 5H).
After 3weeks, H&E staining displayed the presence of hy-
pertrophic chondrocytes in BMP-2-stimulated aggregates
(3D) (black arrows), a phenomenon that was not seen in
2D stimulated cells followed by aggregation (2D-3D) (Fig-
ure 6A). An AB stain confirmed the formation of a dense
matrix rich in GAGs (white arrows) (Figure 6B). These find-
ings were further supported by an MT staining (Figure 6C).
To analyze remodeling of the cartilaginousmatrix, tartrate-
resistant acid phosphatase (TRAP) staining was performed,
which showed positive areas in close vicinity to GAG-rich
areas and hypertrophic chondrocytes (black arrows) (Fig-
ure 6D). Upon quantification, the BMP-2-stimulated aggre-
gates displayed a 2-fold higher percentage of TRAP+ area
(Figure 6E). Remodeling of the cartilage intermediate was
further confirmed by IHC for DIPEN, the cryptic epitope
of ACAN, typically exposed upon its degradation (black ar-
rows) (Figure 6F). To further characterize the cartilaginous
tissue, IHC for S100 confirmed a 6-fold higher positive
area in BMP-2-stimulated aggregates (black arrows) (Figures
6G and 6H). Furthermore, amature cartilaginous tissue was
confirmed by IHC for Indian hedgehog (Ihh), expressed by
(pre)hypertrophic chondrocytes (black arrows) (Figures 6I
and 6J).
After 6 weeks, the 3D stimulated tissue intermediate had
further developed along the endochondral route to form
ectopic mineralized tissue (Figure 6K). Formation of bone
ossicles were confirmed through H&E and MT staining.
Bone (black arrows) and bone marrow (red arrows) were
observed as well as zones of mature bone (green arrows)
(Figure 6L). Active remodeling (blue arrows) was indicated
by a TRAP staining while contribution of the implanted
cells was confirmed by IHC specific for human osteocalcin
(hOCN). These data confirm the in vivo maturation and
reveal that the combined approach of cell aggregation
and exposure to BMP-2 induced in vivo tissue develop-
ment in a process closely resembling endochondral bone
formation.
Healing of a Critical Size Long-Bone Defect
Based on the ectopic endochondral development of the
in vitro primed microtissues, the orthotopic behavior
was next assessed in a critical size tibia defect in immuno-
deficient mice. Upon transplantation, the in vitro BMP-
2-stimulated aggregates led to bridging within 4 weeks as
assessed by X-ray analysis in five of six animals (Figure 7A).
Non-unions were confirmed in four of five controls up to
8 weeks after the creation of the defects. Full bridging
by a mineralized matrix at 4 and 8 weeks was confirmed
by nano-computed tomography scanned explants (Fig-
ure 7B). Qualitative analysis was assessed by histology766 Stem Cell Reports j Vol. 8 j 758–772 j March 14, 2017and IHC. H&E and Safranin O/fast green staining revealed
a cartilage intermediate 2 weeks post implantation (Figures
7C and 7D). Hypertrophic chondrocytes were present
(gray arrows) in the center of the cartilaginous callus,
whereas a mineralized tissue had started to form in the
periphery, the latter being visualized byMT staining (black
arrows) (Figure 7E). The early cartilage intermediate dis-
played positivity for TRAP (blue arrows), suggesting re-
modeling of the mineralized cartilaginous intermediate,
a process that was maintained at week 4 but decreased
at week 8 (Figure 7F). Moreover, the cartilage callus dis-
played positivity for hOCN, depicted by a brown stain
(white arrows), confirming the contribution of donor cells
(Figure 7G). At 4 weeks, a fully mineralized bridging was
observed, where the MT staining showed more mature
mineralized zones, indicated by red zones (yellow arrows)
(Figure 7E). This mineralized tissue stained positive for
hOCN (white arrows) (Figure 7G). After 8 weeks, the
mineralized matrix displayed more zones of mature bone
which was also confirmed to be positive for hOCN (white
arrows) (Figures 7F and 7G). In addition, qualitative anal-
ysis confirmed the absence of cartilage or osseous tissue
in control non-unions as well as a negative staining for
hOCN (Figures 7C–7G). These data demonstrate a success-
ful bridging of a critical size fracture by an in vitro primed
cell-based construct.DISCUSSION
Cell-based ATMPs represent an opportunity for the qualita-
tive long-term cure of incapacitated organs or tissues lack-
ing adequate intrinsic biological potential to heal (Einhorn
and Gerstenfeld, 2015). Despite scientific breakthroughs,
only a fraction of the developed ATMPs today reaches suc-
cess in clinical translation for many reasons, including the
poor design of the ATMP, modest outcomes in rigorous
clinical trials, manufacturing challenges, and cost of goods
(Erben et al., 2014). To drive successful clinical translation,
a deeper understanding of the basic biology that underlies
(1) the mechanism of the healthy repair process that is
failing and (2) the design of the engineered construct, is
required (Loh et al., 2016). As a driving force in developing
a clinically effective ATMP for large long-bone defect heal-
ing, the choice of progenitor cells is of importance where
the periosteum represents a relevant tissue source. Autolo-
gous hPDCs can be isolated at the site of the fracture
without a second surgery. However, there are limitations
in terms of the amount of tissue available. The use of allo-
genic cells may allow harvest of larger tissues depending on
the donor, but comprises the risk of disease transmission
and immune response (Morizane et al., 2013). Conse-
quently, current cell culture protocols focus on achieving
Figure 6. The Combined In Vitro Priming by BMP-2 Treatment and Aggregation Led to Endochondral Bone Formation In Vivo
Histology on tissue constructs 3 weeks after in vivo subcutaneous implantation demonstrated that the simultaneous stimulation by
aggregation and BMP-2 affected in vivo tissue formation.
(A) H&E staining displayed the presence hypertrophic chondrocytes (black arrows) next to denser ECM areas (white arrows).
(B) Denser AB stain lines the zones of hypertrophic chondrocytes (white arrows) surrounded by GAG-rich areas (white arrows).
(C) The MT stain confirmed the formation of denser areas (black arrows).
(D and E) TRAP-positive areas (black arrows) surrounding the hypertrophic chondrocytes suggest remodeling (D) and quantification (E).
(F) IHC for DIPEN showed breakdown of GAG-rich areas.
(G and H) IHC for S100 displayed more mature cartilage tissue in BMP-2 stimulated aggregates (G), confirmed by quantification (H).
(I and J) IHC for Ihh showed the presence of hypertrophic chondrocytes (I), which upon quantification was a 4-fold higher compared with
2D-stimulated cells (J).
(K) At 6 weeks, the endochondral tissue intermediate had developed into a mineralized ossicle.
(L) H&E staining confirmed de novo formed bone (black arrows) and bone marrow (red arrows), while MT staining displayed zones of mature
bone (green arrows). TRAP staining suggested ongoing remodeling of immature bone (blue arrows) and IHC for hOCN confirmed the
contribution of the implanted cells. Unlabeled scale bars, 20 mm. n = 4, *p < 0.05, **p < 0.01.
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Figure 7. The In Vitro Primed Cell-based Tissue Construct Led to the Healing of a Critical Size Long-Bone Defect
(A) In vivo X-ray monitoring of fracture healing upon transplantation of in vitro BMP-2-stimulated microaggregates.
(B) Reconstructed images from nano-computed tomography scanned explants displayed mineralized healing of the critical-sized defect
4 weeks post transplantation.
(C–G)Qualitative analysis of sectioned explants 2, 4, and8weeks post transplantation, including control confirmingnon-union. Cartilage and
bone formation was confirmed by H&E (C), Safranin O and fast green (D), and MT (E) staining. Tissue remodeling was investigated by a TRAP
stain (F), whereas contribution of implanted cells was confirmed by IHC for hOCN (G). Arrows indicate specific tissues as follows: cartilage
(gray), bone (black), mature bone (yellow), TRAP-positive areas (blue), hOCN-positive cells, andmatrix (white). Unlabeled scale bar, 50 mm.
768 Stem Cell Reports j Vol. 8 j 758–772 j March 14, 2017
a fast and efficient expansion phase without an apprecia-
tion of maintenance of the progenitor potential.
In addition, recent findings indicate that the majority
of in vitro expanded cells undergo apoptosis upon implan-
tation (Stegen et al., 2016). A cause may be the need to
instantly adjust to a compromised environment, since cur-
rent culture conditions represent a rather non-physiolog-
ical and abundant nutritional source. Optimized culture
conditions for clinically relevant progenitors are therefore
essential for the in vitro preparation of cell-based con-
structs and should maintain cell survival, allow efficient
growth factor treatments without batch-to-batch variation,
andmeet the regulatory guidelines (Dimarakis and Levicar,
2006).
We developed a serum-free pre-conditioning regime in a
CDM in order to adapt/prepare progenitor cells for differ-
entiation and the subsequent in vivo environment. Of
note, pre-conditioning in CDM led to an increased DNA
content per cell, but no cell proliferation or change in kar-
yotype profile. This suggests the onset of endoreplication,
a phenomenon where cells replicate the nuclear genome
in the absence of cell division, leading to elevated DNA
content and enhanced cell potential in order to save en-
ergy (Edgar and Orr-Weaver, 2001). This was further sup-
ported by increasedmRNA transcript levels of the cell cycle
markers CCNE1, CDK1, and BIRC5 (Banyai et al., 2016;
Britton and Edgar, 1998; Yamamoto et al., 2008). Although
the mechanism of endoreplication is not yet fully under-
stood, studies in mice have shown improved adaptation
to stress and/or limited energy sources, typically seen dur-
ing tissue regeneration (Pandit et al., 2013; Sher et al.,
2013). Although more studies are needed in order to eluci-
date whether cells from the periosteum adapt this mecha-
nism after the initial proliferative burst in fracture healing,
this may be a potential cause of their remarkable regenera-
tive capacity (Roberts et al., 2015), a phenomenon partially
replicated by the pre-conditioning.
Furthermore, a dramatic shift in MSC marker expression
was seen, including an increased positivity for CD34
(Wood et al., 1997; Fina et al., 1990; Krause et al., 1994).
There is evidence that CD34 is a marker for diverse progen-
itors including MSCs (Copland et al., 2008). In the current
study, mRNA transcript levels of CD34 were higher in
freshly isolated hPDCs grown to confluency. This indicates
that native progenitors from the periosteum may be
CD34+, but the expression is lost upon in vitro expansion.
This is in line with previous reports with murine bone
marrow mononuclear progenitors, defined as a potent os-
teoprogenitor cell population, losing their CD34+ upon
in vitro expansion (Abdallah et al., 2015). Moreover, the
CD34+ cell population displayed an enhanced expression
and secretion of osteoprogenitor-secreted factors (Majka
et al., 2001; Janowska-Wieczorek et al., 2002). In addition,an elevated expression of BMP type 1 and 2 receptors was
seen, suggesting the generation of a more BMP-responsive
cell population (Hidalgo et al., 2012). In line with these
findings, CDM pre-conditioned hPDCs displayed an earlier
onset of, as well as an elevated osteochondrogenic response
to BMP treatment, confirmed by BMP-2, -4, -6, -7, -9, and
GDF5 stimulation. This improved differentiation potential
could be correlated to the CD34+ cell population. In addi-
tion, an altered activation of downstream signaling path-
ways was confirmed in the CDM pre-conditioned cells,
suggesting a potential mechanism to the more potent dif-
ferentiation. Importantly, a change in cellular phenotype
and improved differentiation potential was observed in
cells isolated from donors of different gender and age, in
line with previous reports on the osteochondrogenic ca-
pacity of PDCs (Chang et al., 2014). Of note, a reduced
response was seen in cells isolated from a 47-year-old fe-
male, which was associated with low expression levels of
BMP receptors. Further screening of more samples will be
required to determine whether this is a combined age-
and gender-dependent phenomenon (Nicks et al., 2010).
Since both an elevated osteogenic as well as chondrogenic
differentiation was seen, IHC for SOX9 and OSX was per-
formed to gain information at the single-cell level. Remark-
ably, CDM pre-conditioned cells displayed a positivity for
bothmarkers. Cell-fate studies have revealed that SOX9-ex-
pressing limb bud mesenchymal cells give rise to both
chondrocytes and osteoblasts, where SOX9 expression pre-
cedes RUNX2 and OSX expression during limb bud devel-
opment (Akiyama et al., 2005; Nakashima et al., 2002). As
a consequence, the combined SOX9 and OSX positivity
may reflect the stage when cells enter the hypertrophic
or early osteoblast stage and undergo a transition from
SOX9+ to OSX+ cells. On the other hand, additional
markers such as ACAN, COLL10A1, RUNX2, and OCN are
also upregulated, further opening the possibility of cells
undergoing a dual- or trans-differentiating pathway (Yang
et al., 2014; Zhou et al., 2014). Nevertheless, the elevated
differentiation capacity seen in vitro could be correlated
to an elevated cartilaginous tissue production in vivo. To
further investigate the in vivo potential, a biomimetic sys-
tem in the formof cell aggregationwas introduced (Moreira
Teixeira et al., 2012; Evans et al., 2013). Initially, an optimal
size of the aggregate was determined and an increased
aggregate size led to elevated expression of RUNX2, ALP,
OSX, and VEGF. This could potentially be explained by
the elevated forces exerted by the increased number of cells
in the aggregates, which further steered differentiation to-
ward the endochondral fate (Qi et al., 2008; Mammoto
et al., 2011). Upon ectopic assessment in vivo, a synergistic
effect of aggregation and BMP-2 treatment displayed an
enhanced microvessel ingrowth along with the presence
of GAG-rich matrix and active BMP signaling. It can beStem Cell Reports j Vol. 8 j 758–772 j March 14, 2017 769
speculated that this was due to endogenous BMP produc-
tion suggested by an elevated BMP-2 protein secretion,
further supported by elevated BMP-2 expression on an
mRNA transcript level. Therefore, the endogenous BMP
secretion may further have contributed to in vivo endo-
chondral bone formation (Einhorn, 1998; Schindeler
et al., 2008). After 3weeks in vivo, the presence of hypertro-
phic chondrocytes, cartilage remodeling, and degradation
was observed in constructs where simultaneous stimula-
tion by aggregation and BMP-2 was applied. At week 6,
these constructs had further developed into bone ossicles.
Assessment in a critical size long-bone defect displayed suc-
cessful bone bridging 4 weeks post transplantation. Quali-
tative analysis at 2 weeks displayed a process resembling
endochondral bone healing with the contribution of the
transplanted hPDCs to both the intermediate cartilage tis-
sue as well as the bridging bone. A reduced contribution of
the implanted cells was seen at week 8, suggesting that
host-derived cells are involved in the remodeling of the
newly formed bone tissue.
This study reports the development of a cell-based strat-
egy for the healing of a critical size long-bone defect
through a cartilaginous intermediate using a serum-free,
chemically defined, and biomimetic approach. In vitro
BMP-2 treatment of cell-based bioinspired engineered mi-
crotissues leads to a primed but not mature cartilage tissue,
self-sustained by endogenous production of growth and
differentiation factors. Upon in vivo implantation, tissue
formation is achieved in a process mimicking natural frac-
ture healing. Encouragingly, this approach is applicable for
autologous as well as allogenic progenitor cell populations.
The presented findings represent a fundamental contribu-
tion to the successful development of clinically relevant
cell-based constructs for tissue regeneration and provide
convincing information on the importance of relevant
in vitro conditions for the in vivo outcome.EXPERIMENTAL PROCEDURES
Pre-conditioning in CDM or GM as a control was carried out
for 6 days. Directly following pre-conditioning, BMP-2 stimula-
tion and/or aggregation was carried out for an additional
6 days. In vivo implantation was carried out ectopically and or-
thotopically in NMRInu/nu mice. Cell material was encapsulated
in collagen type 1 gels for implantation. In vivo development
of the implanted constructs was studied for up to 8 weeks.
Detailed experimental procedures are provided in the Supple-
mental Information. The ethical committee for human medical
research (KU Leuven) approved all procedures, and informed
consent was obtained from the patients. All procedures on
animal experiments were approved by the local ethical commit-
tee for animal research (KU Leuven). The animals were housed
according to the guidelines of the Animalium Leuven (KU
Leuven).770 Stem Cell Reports j Vol. 8 j 758–772 j March 14, 2017SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Results, Supple-
mental Experimental Procedures, six figures, and one table and can
be found with this article online at http://dx.doi.org/10.1016/j.
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Figure S1. Serum free pre-conditioning affected hPDC phenotype. Related to Figure 1. 
(A) Flow cytometry analysis of individual hematopoietic markers after six days of pre-conditioning in CDM or 10 % 
FBS. (B) The induced CD34 positivity by CDM pre-conditioning was specific for hPDCs and was not seen in 
hBMSCs. (C) mRNA transcript level of CD34 in passage one (p1) hPDCs from individual donors (HP1 and HP2) and 
hPDCs expanded in GM to passage 6 (p6) pre-conditioned in CDM or GM. (D) Pre-conditioning in CDM affect cell 





Figure S2. The serum free pre-conditioning enhanced both osteogenic and chondrogenic differentiation induced upon 
BMP-stimulation. Related to Figure 2. 
(A) CDM pre-cultured cells followed by BMP-2 stimulation displayed enhanced expression of chondrogenic markers 
COLL2A1, COLL10A1and osteogenic markers RUNX2 and COLL1A1. In addition elevated expression of 
transcriptional regulator DLX5 was seen. The effect of BMP-2 in CDM pre-cultured cells was not only limited to 
BMP-2. (B) Increased expression of ACAN, OCN, DLX5, BMP-2 and VEGF was seen in this pre-culture regimen 
followed by 2D stimulation of BMP-2, BMP-4, BMP-6, BMP-7, BMP-9 and GDF5. (Statistical significance to: BMP-





Figure S3. The improved pre-conditioning effect was confirmed in young and adult donors. Related to Figure 1 and 
Figure 2. 
(A) Pre-conditioning of individual donors (D1-3) and two different pools (P1-2) of cells of different gender and ages 
displayed elevated CD34 expression, (B) as well as adapted expression level of BMP type 1 and type 3 receptors. 
Expression of (C) SOX9, (D) OSX and (E): ID1 following BMP-2 stimulation. (F) Cluster correlation displayed 
association of pre-conditioning in CDM and expression levels of marker genes. (G) Constellation plot over the 
clustered data displayed grouping of the majority of CDM pre-conditioned cell populations over individual 




Figure S4. Serum free pre-conditioning led to enhanced GAG-production in vivo. Related to Figure 1 and Figure 2. 
(A) Histology 3 weeks post subcutaneous implantation by H&E staining of in vivo samples displayed denser matrix 
formation in BMP-2 stimulated cells (black arrows) whereas more fibrous tissue were depicted in non-stimu;ated 
conditions (grey arrows), Alcian blue (AB) displayed cellular condensations (white arrows) surrounded by a GAG 
production in BMP-2 stimulated cells (black arrows) which was confirmed by Masson’s Trichrome (MT) stain (black 
arrows). (B) Upon quantification of percentage of AB positive area, CDM pre-conditioning followed by BMP-2 





Figure S5. The number of cells per aggregate affected aggregate formation. Related to Figure 4 and Figure 5. 
(A) Bright field images after 6 days of aggregation in cell densities of 50, 100 or 250 cells/ aggregate in the presence 
of or without BMP-2 displayed stable formation of aggregates of 100 and 250 cells. (B) Aggregation induced a 





Figure S6. Aggregate size steered in vitro primed lineage specification. Related to Figure 4 and Figure 5. 
(A) IHC for SOX9 (red), OSX (green) and DAPI (blue) on aggregates of 50, 100 or 250 hPDCs/aggregate cultured in 
the presence with or without BMP-2, confirm gene expression data. The results are representative of two or more 
independent experiments. (B) Histology for H&E, Alcian blue and Alizarin red on 6 days aggregated cells with and 





Table S1. Primer sequences used for mRNA transcript analysis. 
Gene Forward sequence Reverse sequence 
SOX9 TGGAGACTTCTGAACGAGAGC CGTTCTTCACCCACTTCCTC 
ACAN GTCTCACTGCCCAACTAC GGAACACGATGCCTTTCAC 
COLL2A1 GGCTTCCATTTCAGCTATGG AGCTGCTTCGTCCAGATAGC 
COLL10A1 ACGATACCAAATGCCCACAG GTGGACCAGGAGTACCTTGC 
RUNX2 CGCATTCCTCATCCCAGTAT GCCTGGGGTCTGTAATCTGA 
OSX AGTGACCTTTCAGCCTCCAA GGGAAAAGGGAGGGTAATCA 
COLL1A1 GACGAAGACATCCCACCAAT AGATCACGTCATCGCACAAC 
OCN GTGCAGCCTTTGTGTCCAA GCTCACACACCTCCCTCCT 
DLX5 CAGCCAAAGCTTATGCCGAC CGGTCACTTCTTTCTCTGGCT 
ID1 GGCTGTTACTCACGCCTCAAG CCAACTGAAGGTCCCTGATGTAG 
VEGF TGCAGATTATGCGGATCAAACC  TGCATTCACATTTGTTGTGCTGTAG  
BMP-2 GTATCGCAGGCACTCAGGTC TTTTCCCACTCGTTTCTGGT 
FGF2 AAAAACGGGGGCTTCTTCCT TGTAGCTTGATGTGAGGGTCG 
ALK1 ATCTGAGCAGGGCGACAC ACTCCCTGTGGTGCAGTCA 
ALK2 ATGTGACCAAGAGCCTGCAT CGCAGGAGAGACCTTCACAC 
ALK3 CAGGGCACTGTCCAGATGAT AGCTGGGCTTTTGGAGAATC 
ALK6 ATGACTCTGGGTTGCCTGTG TCAATGGAGGCAGTGTAGGG 
BMPR2 GGTTGGAAACCATCCCACTT TGGTCCCAACAGTCTTCGAT 
ACVR2a CCGGAGATGGAAGTCACACAGCCC TGGGGGTGGTCCTGGGTCTTGA 
ACVR2b GCTGCAGACGGACCCGTGGA GGCCAGGCCCGGGTGTTTCA 
CCNE1 GCCAGCCTTGGGACAATAATG CTTGCACGTTGAGTTTGGGT 
BIRC5 ACCAGGTGAGAAGTGAGGGA AACAGTAGAGGAGCCAGGGA 
CDK1 GGATGTGCTTATGCAGGATTCC CATGTACTGACCAGGAGGGATAG 
CD105 CACTAGCCAGGTCTCGAAGG CTGAGGACCAGAAGCACCTC 








Supplemental experimental procedures 
Cell culture 
Isolation and in vitro expansion of hPDCs were carried out as previously described (De Bari et al., 2001). Cells from 
individual donors: donor1 (D1): 10 years female; D2: 23 years male; D3: 47 years female and two pooled populations: 
pool 1 (P1): 13±4.5 years and pool 2 (P2): 29±16 years, were expanded to passage six (p6) in medium containing 10 
% fetal bovine serum (FBS), further referred to as (GM) as previously described (De Bari et al., 2006, Bolander et al., 
2016). Cells isolated from a 43 years male (HP1) and a 16 years female (HP2) were plated and RNA was isolated after 
confluency was reached at the first seeding, representing p0. The P1 population was used as a representative when 
nothing else stated. For pre-conditioning, cells were cultured for six days in serum free chemically defined media with 
the removal of the growth factor cocktail, β-Glycerophosphate and lineolic acid (patent US20010039050)(Gomez-
Barrena et al., 2015), further defined as serum free chemically defined media (CDM) (see below for component 
specification) or in GM as standard control. DNA content was measured using Quant-iTTM PicoGreen® dsDNA assay 
(Invitrogen, Merelbeke, BE) according to the manufacturer’s instructions (n=3). To evaluate the effect of pre-
conditioning prior to differentiation, BMP-stimulation and/or aggregation was carried out for six days directly 
following pre-conditioning.  
Detailed components in the chemically defined medium 
The serum free chemically defined medium (CDM) consisted equal parts of Dulbecco's Modified Eagle Medium and 
HAM’s F-12 (Invitrogen) supplemented with: antibiotics-antimyocotics solution (100 units/ml penicillin, 100 μg/ml 
streptomycin and 0.25 μg/ml amphotericin B; Invitrogen, Merelbeke, BE), 5 µg/ml ITSTM PREMIX (BD Biosciences), 
2 µg/ml L-α-Phosphatidylethanolamine (Jena Bioscience), 1x10-4 M α-ketoglutaric acid, 1.25 µg/ml Taurine, 0,25 
U/ml Cerulosplasmin, 5 µg/ml Cholesterol, 10 µg/ml L-gluthatione reduced, 1,25 µg/ml Taurine, 9x10-7 M D-α-
tochopherol succinate, 50 µg/ml L-ascorbic acid 2 sulphate, 1,6x10-9 M 3,3’,5-Triiodo-L-thyronine sodium salt, 1x10-
9 M Hydrocortisone and 5x10-10 M Parathyroid hormone (Sigma-Aldrich). 
Flow cytometry  
Flow cytometry was performed to characterize the expression of stemness markers on human periosteal cells by using 
human MSC Phenotyping kit (130-095-198, Miltenyi Biotec, Leiden, NL). Individual marker expression on hPDCs 
was characterized by staining the cells with human specific CD14-PerCP, CD20-PerCP, CD-34 PerCP-Vio700, CD45-
PerCP, CD105-PE (130-098-072, 130-098-077, 130-097-915, 130-098-145, 130-098-906, Miltenyi Biotec). The 
extracellular staining was performed according to manufacturer’s instructions. In brief, cells were mixed with MSC 
Phenotyping Cocktail or individual antibodies and incubated in dark at 4°C. After staining, the cells were washed and 
analysed using BD FACS CantoTMcell analyser (BD Biosciences, Erembodegem, BE) with FlowJo V10 software. The 
number of cell surface receptors expressed per cell was quantified using BD QuantiBRITETM-Phycoerythrin beads 
(BD Biosciences, San Jose, CA),) as previously described (Pannu et al., 2001). 
Cell separation 
Separation of CD34+ cells was performed with a COLiso Magnetic Separation Kit-Human CD34+Cells according to 
the manufacturers’ instructions (K10134, ProMab Biotechnologies, Richmond, US). Upon separation, 94% purity of 
CD34+ cells of which 100% were CD14-, CD20- and CD45-, as confirmed by flow cytometry. 
Karyotype analysis 
Genomic DNA was extracted using the QIAamp DNA Blood Mini QIAcube Kit on the Qiacube robotic workstation 
according to the manufacturer’s instructions. Array analysis was performed using the 8x 60K CytoSure ISCA v2 
microarray (AMADID 020040, Oxford Gene Technology, OGT, Oxford, UK). Genomic DNA was labeled for 2 hours 
using the CytoSure Labelling Kit (Oxford Gene Technology). The sample was labeled with Cy5 and hybridized versus 
Cy3-labeled sex-matched reference DNA. Hybridization was performed for minimum 16 hours in a rotator oven 
(SciGene, CA, US) at 65 °C. Washing of arrays was performed using Agilent wash solutions with a Little Dipper 
Microarray Processor (SciGene). Arrays were scanned using an Agilent microarray scanner at 2-µm resolution, 
followed by calculation of signal intensities using Feature Extraction software (Agilent Technologies).Visualization 
of results and data analysis were performed using the CytoSure Interpret Software (Oxford Gene Technology) and the 
circular binary segmentation algorithm. Quality control metrics are monitored with CytoSure Interpret software 
(Oxford Gene Technology). 
In vitro BMP-stimulation and evaluation 
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Pre-conditioned cells were seeded at a cell seeding density of 10 000 cells/cm2 followed by stimulation in CDM or 
GM containing 10% FBS supplemented with 100ng/ml BMP-2 (Medtronics, Minneapolis, Minnesota, US), BMP-4, 
-6, -7, -9 or GDF6 (Peprotech, London, UK). To investigate in vitro differentiation, samples were collected for DNA 
quantification and Alkaline phosphatase (ALP) activity was measured using a commercial kit (Kirkegaard & Perry, 
Guilford, UK) normalized to DNA content. mRNA analysis were performed as previously described (Bolander et al., 
2016), primer sequences are listed in supplementary table 1. To investigate nuclear translocation of downstream 
signalling molecules, Western blot analysis was performed. After 6 days of BMP-2 stimulation, cells were 
homogenised in Cell extraction buffer containing 0.3 M Phenylmethanesulfonyl fluoride and Protease Inhibition 
Cocktail (Sigma-Aldrich, Bornem, BE). Protein concentration was determined using the Pierce BCA Protein Assay 
Kit (Thermo Scientific) according to manufacturer’s instructions. Equal quantities of protein was loaded on NuPAGE 
4-12 % Bis-Tris gels (Invitrogen) and electrophoresed to separate proteins according to size. These proteins were 
subsequently transferred to a Polyvinylidene fluoride membrane by wet transfer for further analysis. Primary 
antibodies were diluted according to the manufacturer`s instructions: rabbit monoclonal Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) (197G2)(43775), rabbit polyclonal p44/42 MAPK (Erk1/2)(9102), rabbit monoclonal 
Phospho-p38 MAPK (Thr180/Tyr182) (12F8)(4631), rabbit polyclonal p38 MAPK(9212), rabbit polyclonal Phospho-
SMAD1 (Ser463/465)/SMAD5 (Ser463/465)/SMAD8 (Ser426/428)(9516), rabbit polyclonal SMAD1(6944), rabbit 
polyclonal SMAD2/3 (5678)(Cell Signalling Technology- BIOKÉ, Leiden, NL), mouse monoclonal Anti-Active-β-
Catenin (05-665)(EMD Millipore, Overijse, BE), goat polyconal Phospho-SMAD2/3 (Ser423/425) (sc-11769)(Santa 
Cruz Biotechnology, Inc, Heidelberg, DE). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mouse 
monoclonal (Abcam) was used to assess equal loading of proteins. HRP-conjugated secondary antibodies were used 
at a dilution of 1:2000 (Jackson, Pennsylvania, US) and images were developed by a LAS3000 Imaging System (FUJI) 
following the application of SuperSignal® West Femto reagent (Thermo Scientific, Illnois, US). Densitometry analysis 
was performed using Biorad Quantity One software. 
3D Microwell fabrication and cell aggregation 
Fabrication of a microwell platform allowing for high throughput production of microaggregates with controlled cell 
density per aggregate was performed as previously described (Leijten et al., 2016). To seed hPDCs in aggregates 
containing 50, 100 or 250 cells/aggregate, the microwells were covered in 2 ml of CDM containing 100.000, 200.000 
or 250.000 cells, respectively, allowing for the formation of 1000 aggregates/well. The stimulatory effect of 
aggregation in combination with or without BMP-2 was investigated by flowcytometry, mRNA transcript analysis 
and IHC. 
In vivo implantation 
Pre-conditioned and 2D stimulated cells or aggregates were washed and collected and 1*106 cells were encapsulated 
in a 100 µl Collagen type 1 gel, (5 mg/mL, BD Biosciences) and implanted subcutaneously in NMRInu/nu mice. In 
addition, BMP-2 stimulated monolayer cultures of hPDCs followed by 24h aggregation in the absence of BMP-2 were 
included to study the effect of separate stimulation of BMP-2 and aggregation. Explants were harvested at 1, 3 and 6 
weeks post implantation and qualitatively analysed by histology and IHC, for all ectopic conditions n=4. For 
orthotopic evaluation, CDM pre-conditioned hPDC were stimulated as aggregates in the presence of BMP-2 for 6 
days. Subsequently after washing, the aggregates were collected and implants of 30 µl collagen type 1 gels (5 mg/mL, 
BD Biosciences) containing 1200 aggregates/gel were prepared. Subsequently, a critical size 4 mm long bone defect 
was created in the right hind tibiae of NMRInu/nu mice, allowing to examine the regenerative bone-forming potential 
of the in vitro prepared construct as previously described (van Gastel et al., 2014). In total, 6 constructs were implanted, 
4 for week 8, 2 for week 4 and 2 for week 2. As control for the critical defect, 5 fractures were made were one was 
excluded from the study due to surgical error with remnants of bone spicules in the fracture. At harvest, samples were 
fixated using 2% paraformaldehyde for 12 h. Explants from the orthotopic model were analysed by ex vivo nano-CT 
as previously described (Bolander et al., 2016), and samples were processed for IHC and histology.  
Immunohistochemistry 
To further identify cell differentiation, IHC was performed by dual immunohistochemistry (IHC) for SOX9 (NB100-
304, NovusBiologicals, Abingdon, UK) and OSX (MAB7547, R&D Systems, Abingdon, UK). As secondary 
antibodies: Alexa 488 anti-mouse, (1:500) together with Biotinylated SP-conjugated goat anti rabbit (1:500) were used 
followed by incubation with Streptavidin Alexa 555 (1:500) (Jackson ImmunoResearch, Philadelphia, US) and DAPI 
(1:2500). Microscopic analysis was performed by confocal imaging using a FluoView FV1000 setup (Olympus) and 
visualized by Z-stacking of images obtained with a UPLSAPO 60x oil objective at 0.265 um x 0.265 um pixel size, 
and images acquired in z-direction were separated by a distance of 1.83 um. To identify in vivo tissue development, a 
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rabbit Phospho-SMAD1 (Ser463/465)/ SMAD5 (Ser463/465)/ SMAD8 (Ser465/467) antibody (Cell signalling, 
Leiden, NL), mouse Aggrecan monoclonal antibody to N-terminal neoepitope (DIPEN) (clone BC4) (1042002, MD 
Bioscience, Switzerland), rabbit polyclonal Anti-S100 (Z0311, Dako, Heverlee, BE) and rabbit polyclonal Anti-Ihh 
antibody - N-terminal (ab80191, abcam, Cambridge, UK) were used according to the manufacturers’ instructions. 
Contribution to de novo formed tissue by implanted cells were investigated using a human specific primary anti-OCN 
guinea pig antibody (a generous gift from Dr. E. Van Herck, Legendo, KU Leuven, BE) which does not cross-react 
with mouse OCN (De Bari et al., 2006). As secondary antibodies, peroxidase-conjugated goat anti-rabbit, -mouse, or 
-guinea pig (Jackson ImmunoResearch) were used. For non-fluorescent IHCs, 3,30-diaminobenzidine (Sigma-
Aldrich) were used as a chromogenic substrate and hematoxylin as counterstain. Tissue sections were visualized with 
an inverted microscope (IX83-P22F, Olympus). 
Histology 
To visualize glycosaminoglycans, samples were stained with acidic Alcian Blue (pH=1, Merck, Damstadt, DE) and 
counterstained with nuclear fast red (Vector Laboratories, Brussels, Belgium). General matrix staining was visualized 
using hematoxyline (Sigma-Aldrich) and eosin staining (Klinipath, Duiven, NL). Masson’s Trichrome staining was 
performed to visualize immature and mature bone tissue by immersing sections in Weigerts iron hematoxylin solution, 
subsequently stained with ponceau-acid fuchsin solution (0.5% ponceau BS, 0.5% acid fuchsin in 10% acetic acid) 
followed by differentiation in 5% phosphomolybdic acid 5% phosphotungstic acid solution. The sections were then 
transferred directly to Mason’s green solution (Klinipath, Olen, BE) before differentiation in 1% acetic acid. TRAP 
stain was performed to localize osteoclast activity as previously described (Bolander et al., 2016). Histological sections 
were visualized using an inverted imaging setup (IX83-P22F, Olympus). 
Histomorphometry 
For semi-quantitative analysis, stained tissue sections were imaged for an overview or at four defined locations per 
section and used as a representative. ImageJ software was used for quantification of positive staining and scanned 
images from 3 sections per explants were utilized for an average value. The color threshold was adjusted to depict the 
positive areas by defining minimum and maximum values for each color on control samples and an in-house developed 
MatLab code was used to quantify the positive area normalised to the total area.  
Investigation of endogenous BMP production 
Endogenous production of BMP-2 was analysed by a human BMP-2 ELISA development kit (Peprotech) in 
conditioned media from 6 days in vitro stimulated conditions. Fresh stimulation media was used as baseline. The 
ELISA was performed according to the manufacturer’s instructions. 
Statistical analysis 
Data are expressed as individual data points with bars representing the average value. Statistical evaluation was 
determined using a non-paired unequal variance student t-test to compare between independent groups. Statistical 
significance is indicated on all graphs as follows between conditions: *:p < 0.05, **: p < 0.01, ***: p< 0.001 if nothing 
else is stated. Results are conducted from at least 3 independent experiments, n=3 for in vitro data and n=/>4 for in 






The improved effect of serum free pre-conditioning was not age or gender dependent 
The effect of the serum free pre-conditioning was confirmed in young and adult donors (D1-3) as well as in two cell 
pools with a different age average (P1-2) in which an elevated CD34 expression was correlated to enhanced expression 
of BMP-receptors (Figure S3A and B). In addition, BMP-2 stimulation induced elevated differentiation confirmed by 
SOX9, OSX and ID1 expression (Figure S3C-E). Importantly, with ID1 expression as an example, the coefficient of 
variance was a 5-, 2-, 8-, 6- and 14-fold higher in serum conditions for the D1-P2 populations, respectively. 
Interestingly, the effect of the pre-conditioning led to a specific cluster correlation depending on the pre-conditioning 
(Figure S3F). A constellation plot displayed that pooled cell populations can function as a representative for individual 
donors, since the improved potential was independent of gender and age, but potentially affected by combined donor 
characteristics (Figure S3G).  
Enhanced in vitro differentiation leads to elevated cartilaginous matrix deposition in vivo 
To investigate the in vivo effect of the pre-conditioning regimen, BMP-2 stimulated cells were encapsulated in a 
COLL1 gel and implanted ectopically for three weeks to evaluate the potency of the cells to produce cartilage. H&E 
staining displayed denser staining in BMP-2 stimulated explants, which was further elevated in CDM pre-conditioned 
cells (black arrows) (Figure S4A). Fibrous tissue was mainly depicted in non-stimulated cells (grey arrows). The 
deposition of a glycosaminoglycan (GAG)-rich matrix by Alcian Blue (AB) staining demonstrated the presence of 
GAGs in BMP-2 treated implants (black arrows). Image quantification corroborated denser stain in CDM pre-
conditioned cells followed by BMP-2 stimulation combined with cellular condensations (white arrows) (Figure S4B). 
The AB staining was further confirmed by Masson’s Trichrome (MT) with denser areas indicated by black arrows 
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